The World Health Organization (WHO) is facing renewed pressure to evaluate the global regulatory approach to nicotine as public health concerns shift toward modern, non-combustible products. While the medical consensus remains firm that traditional cigarettes are the leading cause of preventable death, the rise of synthetic nicotine products—including e-cigarettes and nicotine pouches—has prompted a formal request from the nation of Palau for a comprehensive review of nicotine’s legal status, which could influence international policy by 2028. This potential move toward stricter oversight highlights a growing debate among global health policymakers: whether the addictive nature of nicotine itself warrants prohibition, even when the severe health consequences of combustible tobacco are removed.
As a physician, I have observed the evolving landscape of tobacco control for over a decade. The core of this issue lies in the distinction between the harmful delivery systems—such as smoke inhalation—and the addictive chemical component itself. According to the World Health Organization, nicotine is highly addictive, and while it is not the primary cause of cancer and heart disease associated with smoking, its potential for dependence remains a significant public health challenge, particularly among younger populations.
The Evolution of Tobacco Control Policies
For decades, international tobacco control has been anchored by the WHO Framework Convention on Tobacco Control (FCTC), the first international public health treaty developed under the auspices of the WHO. Since its adoption in 2003, the treaty has guided member states in implementing tax increases, packaging restrictions, and public smoking bans to reduce the prevalence of smoking, which the WHO identifies as a primary driver of non-communicable diseases. The historical context provided by figures like Gro Harlem Brundtland, who led the WHO in 2000, emphasized that cigarettes are uniquely dangerous because they are the only consumer product that kills when used as directed.
The current challenge stems from the shift in the marketplace. While traditional cigarette consumption has declined in many high-income nations, the market for nicotine-containing products has diversified. Synthetic nicotine, which does not require tobacco leaves, has allowed manufacturers to bypass some traditional tobacco regulations. This shift has prompted regulators to consider whether existing legal frameworks—designed largely for combustible tobacco—are sufficient to manage the risks posed by modern nicotine delivery systems.
The Debate Over Addiction Without Combustion
A central question for the upcoming WHO expert committee deliberations is the definition of harm. If a product eliminates the carcinogenic tar and carbon monoxide associated with traditional smoking, is the remaining dependence on nicotine an acceptable public health trade-off? Proponents of harm reduction argue that for long-term smokers, switching to lower-risk nicotine products can be a life-saving transition. Conversely, public health advocates express concern that the accessibility of these products risks creating a new generation of nicotine-dependent individuals who might otherwise have remained tobacco-free.
According to the WHO’s technical documentation on electronic nicotine delivery systems, there is no consensus on the long-term safety profile of these products. The uncertainty regarding cardiovascular impacts and the potential for these products to serve as a gateway to traditional smoking complicates the regulatory path forward. The committee’s review will likely focus on whether the addictive properties of nicotine are sufficient grounds for global restriction, regardless of the delivery mechanism’s relative harm compared to combustible cigarettes.
What Happens Next: The Path to 2028
The process initiated by Palau is a multi-year effort that involves rigorous scientific assessment by the WHO Expert Committee on Drug Dependence (ECDD). The ECDD is tasked with evaluating the abuse potential, medical utility, and public health risk of substances. Their findings will eventually be presented to the UN, where member states will determine the scope of international control measures. This process is expected to culminate in a formal vote or policy declaration around 2028.
For stakeholders—including healthcare providers, policymakers, and consumers—this period is critical for monitoring emerging data. The WHO maintains updated portals regarding the committee’s work schedule and public call for submissions. As the global health community moves toward this milestone, the focus remains on balancing the imperative to protect populations from nicotine dependence with the practical reality of harm reduction in a world where millions are already struggling with smoking cessation.
How do you view the role of nicotine in modern public health? Is total prohibition the right goal, or should the focus remain on harm reduction? Share your thoughts in the comments below or join the discussion with our community of global health readers.
Keep reading